Cue Biopharma, Inc. (NASDAQ:CUE) CEO Daniel R. Passeri Purchases 30,000 Shares

Cue Biopharma, Inc. (NASDAQ:CUE) CEO Daniel R. Passeri purchased 30,000 shares of Cue Biopharma stock in a transaction dated Monday, December 16th. The shares were bought at an average cost of $1.03 per share, for a total transaction of $30,900.00. Following the transaction, the chief executive officer now directly owns 164,578 shares of the company’s stock, valued at approximately $169,515.34. The trade was a 22.29 % increase in their position. The purchase was disclosed in a legal filing with the SEC, which is accessible through this hyperlink.

Cue Biopharma Trading Down 1.0 %

Shares of NASDAQ CUE opened at $1.01 on Friday. The company has a quick ratio of 2.22, a current ratio of 2.22 and a debt-to-equity ratio of 0.05. The stock’s 50 day moving average price is $1.31 and its two-hundred day moving average price is $1.04. Cue Biopharma, Inc. has a 52-week low of $0.45 and a 52-week high of $3.20. The stock has a market capitalization of $63.98 million, a P/E ratio of -1.12 and a beta of 1.66.

Institutional Investors Weigh In On Cue Biopharma

Institutional investors have recently made changes to their positions in the company. GSA Capital Partners LLP boosted its holdings in shares of Cue Biopharma by 5.1% in the 3rd quarter. GSA Capital Partners LLP now owns 291,663 shares of the company’s stock valued at $221,000 after buying an additional 14,104 shares during the period. Geode Capital Management LLC lifted its holdings in Cue Biopharma by 3.3% in the third quarter. Geode Capital Management LLC now owns 508,827 shares of the company’s stock worth $385,000 after acquiring an additional 16,371 shares during the last quarter. Point72 Asia Singapore Pte. Ltd. acquired a new position in Cue Biopharma in the second quarter valued at approximately $66,000. Good Life Advisors LLC grew its holdings in shares of Cue Biopharma by 23.1% during the third quarter. Good Life Advisors LLC now owns 400,000 shares of the company’s stock valued at $303,000 after purchasing an additional 75,000 shares during the last quarter. Finally, Sigma Planning Corp raised its position in shares of Cue Biopharma by 50.9% during the 3rd quarter. Sigma Planning Corp now owns 401,325 shares of the company’s stock worth $304,000 after purchasing an additional 135,295 shares during the period. 35.04% of the stock is currently owned by institutional investors.

Cue Biopharma Company Profile

Cue Biopharma, Inc, a clinical-stage biopharmaceutical company, develops a novel class of injectable therapeutics to selectively engage and modulate targeted, disease relevant T cells directly within the patient's body. Its lead drug product candidate is CUE-101 for the treatment of human papilloma virus (HPV16+)-driven recurrent/metastatic head and neck cancer.